



King's Research Portal

DOI:

[10.1002/hep.27884](https://doi.org/10.1002/hep.27884)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Liberal, R., Grant, C. R., Holder, B. S., Cardone, J., Martinez-llordella, M., Ma, Y., Heneghan, M. A., Mieli-
vergani, G., Vergani, D., & Longhi, M. S. (2015). In autoimmune hepatitis type 1 or the autoimmune hepatitis-
sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production
and impaired suppression. *Hepatology*, 62(3), 863-875. <https://doi.org/10.1002/hep.27884>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Table 1. Demographic, laboratory and clinical data

AILD n=43	Sex (F/M)	Age (years)	AIH/ AISC	IBD (disease activity)	AST (nv<50IU/l)	γ GT (nv<55IU/l)	Bilirubin (nv<20 μ mol/l)	IgG (nv:6.5-17 g/l)	Autoantibody titer*			IS treatment	Assay performed
									ANA	SMA	LKM-1		
[A] patients	11/7	5.6-16.8 (14.1)			51-1061 (102)	6-505 (65)	3-127 (14)	11.7-43.9 (18)	0-160 (20)	0-640 (20)	0		
A1#	M	5.6	AISC	-	294	492	7	18.12	0	320	0	-	p
A2#	F	9.3	AIH	-	75	98	24	13.83	40	0	0	-	p
A3#	M	10.3	AISC	-	534	50	47	25.64	20	80	0	-	p, f
A4	M	10.5	AIH	-	75	6	125	15.02	20	40	0	P+A	s
A5	F	11.1	AIH	UC (++)	61	55	73	22.17	20	0	0	P+A	p
A6	M	12.1	AISC	UC (+)	93	107	9	11.99	0	0	0	P+A	p, f
A7	F	12.1	AIH	-	64	17	10	16.5	80	80	0	P+A	p
A8#	F	13.5	AIH	-	1061	38	127	43.96	0	20	0	-	p, f
A9#	M	13.8	AISC	UC (+)	51	226	3	18.44	40	0	0	-	p
A10	F	14.4	AISC	-	112	54	7	11.66	40	0	0	P+A	p, c
A11	F	14.5	AISC	-	81	503	24	18.07	0	0	0	P+A	p
A12	M	14.9	AISC	-	111	47	15	16.58	0	40	0	P+MMF	p
A13#	F	15.2	AIH	-	391	54	13	25.83	80	640	0		p
A14	M	15.5	AIH	-	60	12	120	14.19	0	20	0	P+A	f, s
A15	F	15.8	AIH	-	296	105	13	32.12	0	0	0	P+MMF	pa
A16	F	16.4	AISC	UC (+)	125	455	12	17.1	0	40	0	P+MMF	p
A17	F	16.8	AIH	-	197	74	8	18	40	80	0	P+A	p
A18	F	16.7	AISC	UC (+)	59	169	24	17.57	160	0	0	P+A	f
[R] patients	11/14	8.2-32.3 (13.2)			18-49 (28) [¶]	6-164 (22) ^{§§}	4-18 (7) [§]	7.5-27.1 (12.8) [‡]	0-160 (0)	0-160 (0)	0		
R1	M	8.2	AISC	-	30	42	8	22.93	160	0	0	P	p, c
R2	M	8.9	AIH	CD (+)	21	39	7	17.3	40	0	0	P	p, c
R3	F	9.5	AISC	-	27	21	4	17.06	40	0	0	P+A	p, c
R4	M	9.7	AIH	-	33	11	5	8.42	40	0	0	P	pa, s
R5	M	10.1	AIH	-	40	26	7	17.8	0	0	0	P	p, f
R6	M	10.4	AIH	-	36	14	5	7.71	0	0	0	P	p
R7	F	10.5	AIH	-	28	33	6	13.16	0	80	0	P+A	p
R8	M	11.7	AIH	-	22	20	4	14.63	10	0	0	P	p
R9	F	12.7	AIH	-	49	45	6	21	160	0	0	P+A	p
R10	F	12.7	AISC	UC (++)	41	164	5	27.14	0	160	0	P+A	p, c
R11	M	13	AIH	-	22	8	7	8.98	160	0	0	P+A	p, c

R12	F	13.2	AIH	-	27	10	6	20.8	0	0	0	P+A	p, s
R13	M	13.2	AIH	UC (+)	24	18	7	12.44	0	0	0	P	p, c
R14	M	14.8	AIH	-	48	34	18	10.68	0	0	0	P	s
R15	M	15.7	AISC	UC (+)	21	12	4	12.4	0	0	0	P	f, s
R16	M	16.1	AISC	UC (+)	47	91	14	12.99	160	0	0	P+A	p, c
R17	F	16.5	AIH	-	28	23	9	14.04	0	0	0	P+MMF	pa, s
R18	F	16.5	AIH	-	33	22	6	12.89	0	0	0	P+A	p
R19	F	16.7	AISC	UC (+)	33	49	5	11.29	0	0	0	P	p, c
R20	M	17.1	AIH	-	28	28	13	11.06	0	0	0	P+A	p
R21	M	17.8	AIH	-	18	35	11	7.51	0	0	0	P+A	p
R22	F	23.5	AIH	-	19	6	11	12.61	40	40	0	P	s
R23	M	26.7	AISC	UC (+)	43	27	8	12.21	80	0	0	P	p, c
R24	F	27.9	AIH	-	18	11	6	20.08	40	0	0	P+A	f, pa, s
R25	F	32.3	AIH	-	35	12	7	9.79	160	0	0	P	s

Cumulative data from [A] e [R] patients presented as range (median)

AILD: autoimmune liver disease

[A] patients: patients with active disease

[R] patients: patients at remission

AIH: autoimmune hepatitis; AISC: autoimmune sclerosing cholangitis

IBD: inflammatory bowel disease (disease activity determined on the basis of clinical, histological [i.e. presence of neutrophils in the crypts] and serological [i.e. levels of fecal calprotectin] parameters); UC: ulcerative colitis; CD: Crohn's disease; +: mild;

++: moderate; no patient had severe IBD at the time of study

AST: aspartate amino transferase

γGT: gamma glutamyl transferase

IgG: immunoglobulin G

*: Autoantibody titer shown as reciprocal

ANA: anti-nuclear antibody

SMA: smooth muscle antibody

LKM-1: liver kidney microsomal antibody type 1

IS treatment: immunosuppressive treatment

P: prednisolone

A: azathioprine

MMF: mycophenolate mofetil

p: phenotype analysis

c: cytokine profile

f: function

pa: polarization assay

s: p-STAT5 determination

#: patients studied at disease presentation before starting immunosuppression

[¶]P=0.01, ^{¶¶}P=0.01, [§]P=0.03, [‡]P=0.03 when comparing AST, γ GT, bilirubin and IgG levels between [A] and [R] patients

Figure 1




Figure 1 continued




Figure 5

